home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410m.zip
/
M94A2367.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
47 lines
Document 2367
DOCN M94A2367
TI Does HTLV-II coinfection predict clinical progression in HIV-infected
drug users?
DT 9412
AU Hershow RC; Fukuda K; Graber J; Vlahov D; Rezza G; Klein RS; Des Jarlais
D; Vitek C; Galai N; Khabbaz R; et al; Univ. of Illinois at Chicago,
School of Public Health, Epi/Bio; Dept. 60612.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):320 (abstract no. PC0210). Unique
Identifier : AIDSLINE ICA10/94370208
AB OBJECTIVES: To determine if coinfection with HTLV-II is associated with
more rapid development of pre-AIDS bacterial pneumonia/sepsis (BPS),
AIDS (1987 definition), or HIV-related mortality in HIV-infected
injecting drug users (IDUs). METHODS: IDUs with known HIV-seroconversion
dates (last negative to first positive < or = 2 yrs) were enrolled from
4 longitudinal cohort studies. We assayed HTLV infection by EIA and
confirmed and typed by Western Blot. Proportional hazards models were
used to assess the association of each clinical outcome with HTLV-II
coinfection, seroconversion age (SCAGE) and gender. RESULTS: In 370
HIV-infected IDUs, 61 (16%) were HTLV coinfected; all coinfections were
HTLV-II. Median SCAGE in coinfected persons was 39 compared to 29 yrs (p
< 0.001) in the HIV-singly infected. AZT was used by 23% in both groups.
Median followup was 3.1 yrs during which 38 BPS, 45 AIDS and 28
HIV-related mortality events ensued. In univariate models, HTLV-II was
associated with BPS (RR = 2.8, p = 0.003), mortality (RR = 2.7, p =
0.02), but not AIDS (RR = 1.0); SCAGE was associated with BPS (RR = 1.07
per year, p = < 0.001) and was marginally associated with mortality (RR
= 1.04, p = 0.053); gender was not associated with any outcome. In
models with both SCAGE and HTLV-II, HTLV-II was not significantly
associated with BPS (RR = 1.5, p = 0.31) or mortality (RR = 2.2, p =
0.12); SCAGE was associated with BPS (RR = 1.06, p < 0.001).
CONCLUSIONS: HTLV-II does not significantly modify clinical progression
to BPS, AIDS, or HIV-related mortality in HIV-infected IDUs after
adjustment for SCAGE. Combined with results presented elsewhere, which
revealed no HTLV-II effect on the rate of CD4 decline in this cohort,
these findings suggest that HTLV-II does not accelerate progression of
HIV-infection.
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS Adult Age Factors
AIDS-Related Opportunistic Infections Human HIV
Infections/*COMPLICATIONS/MORTALITY HIV Seropositivity HTLV-II
Infections/*COMPLICATIONS Prognosis Proportional Hazards Models
Substance Abuse, Intravenous/*COMPLICATIONS MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).